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ACUTE hemolytic anemia has been observed in sev-
eral occasions among different allograft recipients 
treated with cyclosporine (CyA).'-S The etiology of red 
blood cell (RBC) destruction was either ABO and/or 
Rhesus (Rh) D blood group incompatibility or drug-related 
immune injury. With FK 506 therapy, acute hemolysis was 
noticed in eight patients. The drug was given as a primary 
immunosuppressant in five patients and as a rescue ther-
apy in three. 
MATERIALS AND METHODS 
Patient Population 
Eight out of 1,400 patients who received FK 506 at the University 
of Pittsburgh developed acute hemolysis that required frequent 
blood transfusion. Seven patients were liver transplant recipients 
and one was treated for chronic graft vs host disease (GVHO) 
after an HLA identical bone marrow transplant. FK 506 was given 
as primary immunosuppressant therapy in five patients. The 
rescue group (n = 3) received CyA, azathioprine, and steroids 
before the FK 506 treatment. Of the eight patients, five were men 
and three were women with a mean age of39 ::!: 14 (range 12 to 65). 
All patients received ABO identical grafts. Only one Rh-positive 
liver recipient received a Rh-negative graft (Table I). In three of 
the seven liver recipients, direct T-Iymphocyte cytotoxic cross-
matches were strongly positive with 100% plasma renin activity 
(PRA). 
A posttransplant Iymphoproliferative disorder (LPO) was doc-
umented in three liver transplant recipients at the time of hemo-
lysis. In one case, the diagnosis was made before the start of FK 
506 therapy with involvement of the cervical, thoracic. and 
abdominal lymph nodes. In the other two patients, the LPO 
involved the liver and the diagnosis was made in the graft after 
retransplantation. Also, cytomegalovirus (CMV) infection was 
detected at the time of hemolysis in three other liver recipients 
with isolation of the virus from more than one organ. These three 
patients were treated with OHPG. 
At the time of hemolysis, the 12-hour trough plasma levels of 
FK 506 were within the therapeutic range in all cases (0.5 to 2.7 
nglmL). All patients were receiving prophylactic doses of Myco-
statin, Bactrim, acyclovir. and pepcid. In two patients, different 
antimicrobial agents were given because of life-threatening infec-
tions. The patient with GVHO was receiving amoxicillin for 
treatment of chronic sinusitis. Two of the patients received a 
3-day course of OKT3 for the treatment of persistent rejection. 
Hemolytic Studies 
Blood samples were drawn daily for routine hematology, bio-
chemistry, serology. and FK 506 plasma levels. The serologic 
tests consisted of RBC antibody screening and a complement-
dependent RBC cytotoxic test evaluating the in vitro effect of FK 
506 (Table 2). All patients were thoroughly evaluated for bacteri-
ologic evidences of systemic or local sepsis. RBC life span and 
splenic sequestration studies were performed in three patients and 
bone marrow biopsies were done in four. 
Complement-Dependent RBCs Cytotoxic Test 
RBCs from five healthy individuals with 0 Rh(+ve) blood type 
were tested using serial dilutions of anti-H reagent and different 
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Table 1. Demographics of the Patients 
Patient FKS(J6 Blood Type 
No. Age/Sex Diagnosis Transplant Crossmatch Therapy Donor Recipient 
1 431F Sclerosing cholangitis OLT -ve Primary A(+ve) A(+ve) 
2 65/F Hemochromatosis OLT +ve Primary A(+ve) A(+ve) 
3 331M Alcoholic cirrhosis OLT +ve Primary O(+ve) O(+ve) 
4 40/M Hepatitic Cirrhosis OLT +ve Rescue O(+ve) O(+ve) 
5 45/M Hepatitic cirrhosis OLT -ve Primary A(-ve) A(+ve) 
6 461M Hepatitic cirrhosis OLT -ve Primary AB(+ve) AB(+ve) 
7 121M Biliary atresia OLT NO Rescue B(+ve) B(+ve) 
8 29/F Acute myeloid leukemia Identical bone -ve Rescue A(+ve) A(+ve) 
marrow 
Abbreviations: OLT. orthOtopic liver ~ptantation: NO, not done. 
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HEMOLYSIS WITH FK 506 THERAPY 
Table 2. The Results of Complement-Dependent Hemolysis 
Test Against Autologous and Allogenic RBC. Undcw Various 
Concentrations of FK 506 
Patient no./ FK 506 Concentration (n9lmL) 
Serum ABC 0 10 20 
Patient 2 
A(+ve)* 
Patient 4 Positive 
O(+ve)* Positive 
Patient 5 NO NO NO 
A(+ve)" 
Patient 8 Positive Positive 
A(+ve)" Positive 
Abbreviation: NO. not done • 
• Identical with the patient blood type. 
concentrations of FK 506 (10 to 20 ng/mL). The RBCs and serum 
--.·..of four patients were also tested for evidence of in vitro hemoly-
sis. The procedure was performed as follows: blood was collected 
from five healthy 0 Rh( +ve) individuals into glass tubes using 
heparin as the anticoagulant and RBCs were separated by differ-
ential centrifugation. After being resuspended in Hank's balanced 
salt solution (HBSS) and washed two times. RBCs were then 
stored in Alsever's solution at 40°C. Stored RBCs were washed 
and resuspended in HBSS with an adjusted count of 1.0 x 104/ ILL. 
The RBCs were then incubated with O. 10. and 20 ng/mL of FK 
506 at 37°C for 24 hours. One microliter from each set of the RBC 
suspension was then added to I ILL of anti-H using twofold serial 
dilutions. After incubation of all wells at room temperature for 45 
minutes. 2 ILL of rabbit complement adequately diluted with 
HBSS were added and then incubated for another 45 minutes. The 
end point for the anti-H was determined when more than 50% of 
RBCs per well were lysed. 
U sing the same technical steps. the RBCs of four patients and 
four ABO identical healthy individuals were incubated with the 
patient and control serums instead of the anti-H reagent. Positive 
results were considered when more than 50% of the RBCs per 
well showed evidence of hemolysis. 
RESULTS 
Signs of Increased RBC Destruction 
In the absence of blood loss. a persistent fall in the 
hemoglobin concentration and a significant drop in the 
hematocrit (Hct) of more than eight points were observed 
in all of the patients with a mean Hct value of 31 1:: 2 before 
the onset of hemolysis and 18 1:: 4 at the time of diagnosis. 
The mean (1::SD) onset of hemolysis was 35 1:: 24 days 
after initiation of FK 506 therapy. All patients required 
RBC transfusion: four were transfused with 5 to 15 U. 
three with 21 to 27 U. and one received 42 U. Total serum 
bilirubin was high in all patients with no evidence of graft 
rejection in the liver recipients. The level of unconjugated 
bilirubin was increased in 63% of the patients (n = 5). 
At time of hemolysis. peripheral blood smears showed 
classic changes of immune hemolysis with spherocytes 
and polychromasia in all patients. Thrombocytopenia was 
concomitant in six patients. The direct. 3.!ld indirect anti-
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globulin tests were positivtdn the Rh-positive transplant 
patient who received the Rh-negative graft. 
The radioactive RBC scans showed short life spans of 
the erythrocytes with rapid uptake by the spleen. The bone 
marrow biopsies showed erythroid predominance and ac-
tive megakaryocyte production. 
In vitro Effect of FK 506 
FK 506 increased the sensitivity of erythrocytes in a 
complement-dependent hemolysis test. Reciprocal titers 
of 20 to 80 were obtained when 0 Rh( +ve) erythrocytes 
from five healthy individuals were tested against an anti-H 
reagent without FK 506. A one to twofold increase in the 
reciprocal hemolytic titers was observed when erythro-
cytes were treated with 10 nglmL of FK 506. The treat-
ment with 20 nglmL increased the titers to a range of I: 160 
to 1:640. 
Consequently. a hemolysis test was carried out using the 
patient's own sera and own erythrocytes. Hemolysis in the 
presence of FK 506 was observed in two patients at IO 
nglmL and 20 ngimL. respectively. Alloreactive erythro-
cytes were also hemolysed in these two patients. 
Survival and Control of Hemolysis 
Hemolysis was successfully controlled in five out of the 
seven liver recipients and in the patient with GVHD. One 
of these five responders died following retransplantation 
without any evidence of recurrent hemolysis. In the re-
maining two cases. destruction of the RBCs continued and 
both patients died of disseminated lymphoproliferative 
disease. 
Augmented steroid therapy stopped the hemolytic pro-
cess in one of the liver recipients. Splenectomy was 
performed in six patients with a satisfactory response in 
only three of them. Donor B lymphocytes were detected in 
three of the surgically removed spleens. In the Rh-positive 
liver recipient who received the Rh-negative graft. the 
hemolytic process was completely controlled by replace-
ment of the graft. In the GVHD patient, hemolysis re-
solved within 5 days after discontinuation of the amoxicil-
lin and reduction of the FK 506 dose. All survivors (n = 5) 
are currently receiving FK 506 with no evidence of hemo-
lysis. . 
DISCUSSION 
Recent pharmacologic studies have demonstrated that FK 
506 binds with high affinity to the erythrocyte membranes 
(unpublished data). The current in vitro study showed an 
increased susceptibility of normal 0 Rh( +ve) RBCs to the 
hemolytic effect of the anti-H reagent in the presence of 
FK 506 with a concentration of 10 to 20 nglmL (Fig 1). 
Such in vitro concentrations are equivalent to the practical 
therapeutic levels since the in vivo FK 506 concentrations 
are usually 8 to 10 times higher in the whole blood 
compared with the plasma. The exact mechanism of such 
adverse effects is unknown. however sensitization of the 
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Fig 1. The effect of FK 506 on complement-dependent hemoly-
sis. 
RBCs by forming an FK 506-erythrocyte complex should 
be considered. 
The complicated clinical course of these morbid patients 
precludes the ability to establish a single etiology for these 
hemolytic episodes. While FK 506 may predispose or 
initiate hemolysis, multiple other potential factors were 
documented in seven patients. These included CMV infec-
tion (n = 3), LPD (n = 3), donor B-lymphocyte population 
of recipient spleen (n = 3). Rh nonidentical graft (n = I), 
and antibiotic sensitivity (n = I). 
The specific mechanism of autoimmunization in most of 
these patients remained unclear. However. in patients with 
CMV infection, various mechanisms have been postulated 
including absorption of immune complexes and comple-
ment, cross-reacting antigen, and a true autoimmune state 
with possible loss of tolerance secondary to the infectious 
organism.9-'1 With the LPDs, the possible role of Epstein-
Barr virus (EBV) infection and/or other unknown immu-
nologic mechanisms may be incriminated. The detection of 
passenger B lymphocytes in the spleen of the Rh-positive 
patient who received the Rh-negative graft highlighted the 
possible role of the donor B lymphocytes in producing 
anti-Rh antibodies. 
With the drug-related immunologic injury of erythro-
cytes, it is not always possible to be certain that the cited 
drug is unequivocally involved in the pathogenesis of the 
hemolytic anemia. In this study. the serum of two patients 
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induced in vitro hemolysis of both pa.tient and ABO 
identical RBCs in the presence of FK 506 with a concen-
tration of 10 to 20 ngimL. One of these two cases showed 
a positive Coombs test and the other was receiving amox-
icillin treatment. The cessation of the hemolytic process 
both clinically and in the in vitro studies after replacement 
of the graft in the first and discontinuation of the antibiotic 
therapy in the second underscores the possible role of 
different serum factors in triggering the immune injury of 
the erythrocytes. 
Various therapeutic modalities were employed in the 
management of the eight patients with satisfactory clinical 
and hematologic response in six. Steroid therapy was 
effective in one patient and splenectomy was curative in 
about 50% of the cases. Replacement of the liver graft was 
mandatory in the Rh nonidentical recipient and discontin-
uation of amoxicillin was effective in the GVHD patient. 
FK 506 therapy was continued in most of these morbid 
cases and all of the survivors are still receiving the proper 
dose of FK 506 without any evidence of RBC injury. 
In conclusion, the hemolytic phenomena observed in 
patients receiving FK 506 seem to be triggered by different 
etiologic factors. The current in vitro results and the high 
affinity binding of FK 506 to the erythrocytic membrane 
may point out the potential role of FK 506 in inducing 
and/or promoting RBC destruction particularly in patients 
with acquired antierythrocyte antibodies. 
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